Table 5.

Frequency of methylation of the BRCA2 gene promoter in other study groups

No	Country	Method	Type of material		Case		Control		Study
			Case	Control	M	U	M	U
1	France	QAMA	Peripheral blood ($n=$ 873)	Peripheral blood ($n=$ 980)	17%	83%	16%	84%	[12]
2	Ukraine	MSP	Tumor tissue ($n=$ 50)	–	50%	50%	–	–	[10]
3	Brazil	MSP	Tumor tissue ($n=$ 50)	–	44%	56%			[13]
4	Israel	QAMA	Peripheral blood ($n=$ 100)	Peripheral blood ($n=$ 89)	0%	100%	0%	100%	[14]
5	Nigeria	MSP	Peripheral blood ($n=$ 14)	–	57%	43%	–	–	[15]
6	Tunis	MSP	Tumor tissue ($n=$ 117)/paired normal tissues ($n=$ 65)	Non-tumor tissue ($n=$ 21)	69%/5%	31%/95%	0%	100%	[16]
7	Korea	MS-MLPA	Tumor tissue ($n=$ 60)/paired normal tissues ($n=$ 60)	–	2%/0%	98%/100%	–	–	[17]
8	Turkey	MS-MLPA	Tumor tissue ($n=$ 77)/paired normal tissues ($n=$ 77)	–	0%/0%	100%/100%	–	–	[18]

MS-MLPA – methylation-specific multiplex ligation-dependent probe amplification; MSP – methylation-specific PCR; QAMA – quantitative analysis of methylated alleles; M – methylated; U – unmethylated.